All In Biotech

Drug Trial Radar · NCT05680155

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

A Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of XW003 in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 211 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

211

Actual

Start

Dec 29, 2022

Primary completion

Jun 12, 2024

Study completion Oct 12, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to investigate the efficacy and safety of XW003 versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone

Conditions

  • T2DM
  • Type 2 Diabetes Mellitus

Interventions

  • EcnoglutideDrug

    Subcutaneous Injection

  • PlaceboDrug

    Subcutaneous Injection with matched volume

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in HbA1cTime frame: Baseline, Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.